- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03622632
Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
February 16, 2020 updated by: Emmanuel Charbonney, Hopital du Sacre-Coeur de Montreal
The goal of this project, is to better understand the fluctuation of the level of uric acid in traumatized patients by making serial measurements during their hospitalization in the intensive care unit.
In addition, the determinants (e.g.
type of trauma, diseases, interventions) of the blood level of uric acid and its association with the development of organ failure will be sought.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
25
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H4J1C5
- Hôpital du Sacré-Coeur de Montreal
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Multiple trauma patients admitted in the trauma center and requiring ICU admission.
Description
Inclusion Criteria:
- Direct admission to trauma center
- ≤ 3h after trauma
- ISS ≥ 16
- Received at least 1L of fluid at ER entrance
Exclusion Criteria:
- Isolated head injury
- Isolated spine injury
- Chemotherapy within the last month
- Hematologic disease
- Chronic hemodialysis
- Uricase treatment within the last week
- Expected death within 48h
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of serial plasmatic uric acid sampling after trauma
Time Frame: 7 days
|
Number of measures collected/number of measures planned
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of resuscitation on uric acid measures
Time Frame: 24 to 48 hours
|
Impact of fluid administration (amount in mL) on the changes of subsequent uric acid blood level
|
24 to 48 hours
|
Clinical predictors of the first blood uric acid (μmol/L) level measured
Time Frame: 12 hours
|
Impact of patient's characteristics and physiological variables on the first measured blood uric acid. Characteristics will include: age (years), gender, Injury severity score, presence of acute renal impairment. Physiological variables will include: lower systolic blood pressure, base deficit, lactate level |
12 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 30, 2018
Primary Completion (Anticipated)
August 1, 2020
Study Completion (Anticipated)
September 1, 2020
Study Registration Dates
First Submitted
July 24, 2018
First Submitted That Met QC Criteria
August 7, 2018
First Posted (Actual)
August 9, 2018
Study Record Updates
Last Update Posted (Actual)
February 18, 2020
Last Update Submitted That Met QC Criteria
February 16, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 263425
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Singapore National Eye CentreCompletedIntraocular Inflammation in ChildrenSingapore